Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Inclusion Criteria

• •Consent
• •A diagnosis of borderline personality disorder (301.83)
• •All subjects will have a ZAN-BPD greater or equal to 9 at randomization.
• •Males and females aged 18-45 years
• •Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrollment
• •Able to understand and comply with the requirements of the study
• •Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
• •Known intolerance or lack of response to quetiapine fumarate, as judged by the investigator
• •Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir
• •Use of any of the following cytochrome P450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids
• •Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomization
• •Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria
• •Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment
• •Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
• •Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension, congestive heart failure) as judged by the investigator
• •Involvement in the planning and conduct of the study
• •Previous enrollment or randomization of treatment in the present study.
• •Participation in another drug trial within 4 weeks prior enrollment into this study or longer in accordance with local requirements
• •Unstable Diabetes Mellitus
• •An absolute neutrophil count (ANC) of 1.5 x 109 per liter
• •Past history of lack of response to an atypical antipsychotic medication or substantial previous side effects will be cause for exclusion.
• •Any medical illness that would interfere with conduct of the study will be cause for exclusion.
• •Pregnant or lactating women and women of childbearing potential not using medically accepted means of contraception.